Corcept Therapeutics
Clinical trials sponsored by Corcept Therapeutics, explained in plain language.
A commercial-stage pharmaceutical company developing drugs for severe metabolic and psychiatric disorders.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug cocktail aims to fight tough gynecological cancers
Disease control Recruiting nowThis study tests a drug called relacorilant, taken as a pill, combined with two standard chemotherapy drugs (nab-paclitaxel and bevacizumab) in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to see if the combination can slow cancer growth or…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental combo trial launches
Disease control Recruiting nowThis study tests whether adding the drug relacorilant to standard chemotherapy can help people with metastatic pancreatic cancer live longer without their disease getting worse. About 60 adults who have not yet been treated for advanced pancreatic cancer will receive the combinat…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug duo aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called nenocorilant combined with the immunotherapy nivolumab in people with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can shrink tumors. About 50 participants w…
Phase: PHASE1, PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for ALS: experimental drug aims to slow muscle decline
Disease control Recruiting nowThis study tests an experimental drug, dazucorilant, in 279 adults with ALS (Lou Gehrig's disease). The goal is to see if the drug can slow the loss of muscle function and improve quality of life over 24 weeks. Participants will receive either the drug or a placebo, and researche…
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug miricorilant tested for fatty liver disease safety
Knowledge-focused Recruiting nowThis early-stage study is testing a single dose of the drug miricorilant in 15 adults with MASH (a type of fatty liver disease) or MASH with cirrhosis. The main goal is to see how the body processes the drug and whether it is safe. This is not a test of whether the drug works, bu…
Phase: PHASE1 • Sponsor: Corcept Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC